©The Author(s) 2025.
World J Transplant. Dec 18, 2025; 15(4): 106938
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.106938
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.106938
Table 2 Sociodemographics, clinical characteristics, outcomes, and treatment, n (%)
| Characteristics | Full cohort (n = 79) | Recurrent AILD (n = 21) | Non-recurrent AILD (n = 58) | Odds ratio (95%CI) | P value |
| Age at diagnosis (years) (mean ± SD) | 41.03 ± 11.94 | 37.29 ± 12.48 | 42.38 ± 11.55 | 0.96 (0.92-1.00) | 0.098 |
| Time from diagnosis to LT (years) (mean ± SD) | 6.24 ± 4.15 | 6.48 ± 4.13 | 6.16 ± 4.19 | 1.01 (0.90-1.14) | 0.760 |
| Age at LT (years) (mean ± SD) | 47.14 ± 11.75 | 43.76 ± 11.99 | 48.36 ± 11.53 | 0.96 (0.92-1.00) | 0.128 |
| Sex | |||||
| Male | 24 (30.4) | 6 (28.6) | 18 (31.0) | 0.88 (0.29-2.66) | 0.833 |
| Female | 55 (69.6) | 15 (71.4) | 40 (69.0) | 1.0 (ref) | |
| Socioeconomic status1 | |||||
| 1 | 11 (13.9) | 4 (19.0) | 7 (12.1) | Ref | - |
| 2 | 32 (40.5) | 10 (47.6) | 22 (37.9) | 0.79 (0.18-3.35) | 0.755 |
| 3 | 20 (25.3) | 5 (23.8) | 15 (25.9) | 0.58 (0.11-2.86) | 0.507 |
| 4 | 6 (7.6) | 0 (0.0) | 6 (10.3) | - | - |
| 5 | 2 (2.5) | 1 (4.8) | 1 (1.7) | 1.75 (0.08-36.28) | 0.718 |
| 6 | 1 (1.3) | 1 (4.8) | 0 (0.0) | - | - |
| 7 | 7 (8.9) | 0 (0.0) | 7 (12.1) | - | - |
| Family history of autoimmune disease2,3 | 12 (20.3) | 3 (20.0) | 9 (20.5) | 0.97 (0.22-4.19) | 0.970 |
| Concomitant autoimmune disease4 | 23 (29.1) | 7 (33.3) | 16 (27.6) | 1.31 (0.44-3.84) | 0.620 |
| Comorbidities | |||||
| Type 2 diabetes mellitus | 9 (11.4) | 2 (9.5) | 7 (12.1) | 0.76 (0.14-4.02) | 0.754 |
| Chronic hypertension | 6 (7.6) | 0 (0.0) | 6 (10.3) | - | - |
| Hypothyroidism | 13 (16.5) | 3 (14.3) | 10 (17.2) | 0.80 (0.19-3.24) | 0.755 |
| Chronic kidney disease | 4 (5.1) | 1 (4.8) | 3 (5.2) | 0.91 (0.09-9.33) | 0.941 |
| AILD etiology | |||||
| AIH | 30 (38.0) | 8 (38.1) | 22 (37.9) | Ref | - |
| PBC | 19 (24.1) | 4 (19.0) | 15 (25.9) | 0.73 (0.18-2.87) | 0.657 |
| AIH/PBC overlap | 17 (21.5) | 6 (28.6) | 11 (19.0) | 1.50 (0.41-5.40) | 0.535 |
| PSC | 10 (12.7) | 3 (14.3) | 7 (12.1) | 1.17 (0.24-5.69) | 0.838 |
| PSC/AIH overlap | 2 (2.5) | 0 (0.0) | 2 (3.4) | - | - |
| PSC/PBC overlap | 1 (1.3) | 0 (0.0) | 1 (1.7) | - | - |
| Child-Pugh score (mean ± SD) | 10.86 ± 1.83 | 11.61 ± 1.16 | 10.58 ± 1.96 | 1.43 (1.03-2.00) | 0.032 |
| MELD score (mean ± SD) | 19.86 ± 7.01 | 22.76 ± 5.47 | 18.81 ± 7.24 | 1.08 (1.01-1.16) | 0.032 |
| MELD-Na score (mean ± SD) | 22.49 ± 6.81 | 24.71 ± 5.41 | 21.69 ± 7.12 | 1.06 (0.99-1.15) | 0.085 |
| Chronic liver disease complications5 | |||||
| Esophageal varices6 | 66 (91.7) | 16 (88.9) | 50 (92.6) | 0.64 (0.10-3.82) | 0.625 |
| Portal thrombosis7 | 11 (14.7) | 3 (15.8) | 8 (14.3) | 1.12 (0.26-4.76) | 0.873 |
| Hepatic encephalopathy | 57 (72.2) | 14 (66.7) | 43 (74.1) | 0.69 (0.23-2.05) | 0.514 |
| Ascites | 70 (88.6) | 20 (95.2) | 50 (86.2) | 3.20 (0.37-27.26) | 0.287 |
| Spontaneous bacterial peritonitis8 | 23 (30.3) | 8 (40.0) | 15 (26.8) | 1.82 (0.62-5.32) | 0.273 |
| Hepatorenal syndrome9 | 6 (7.7) | 1 (4.8) | 5 (8.8) | 0.52 (0.05-4.73) | 0.562 |
| Infection history 6 months after LT | 46 (58.2) | 12 (57.1) | 34 (58.6) | 0.94 (0.34-2.58) | 0.906 |
| History of acute transplant rejection10 | 12 (15.2) | 4 (19.0) | 8 (13.8) | 1.47 (0.39-5.50) | 0.567 |
| Treatment following LT | |||||
| Basiliximab11 | 57 (93.4) | 16 (94.1) | 41 (93.2) | 1.17 (0.11-12.10) | 0.895 |
| Methylprednisolone12 | 71 (100) | 18 (85.71) | 53 (91.37) | - | - |
| Tacrolimus13 | 72 (98.6) | 21 (100) | 51 (98.1) | - | - |
| Mycophenolate13 | 64 (87.7) | 18 (85.7) | 46 (88.5) | 0.78 (0.17-3.46) | 0.747 |
| Cyclosporine13 | 8 (11.0) | 0 (0.0) | 8 (15.4) | - | - |
| Prednisone13 | 73 (100) | 21 (100) | 52 (100) | - | - |
- Citation: Salgado-de la Mora M, Mendez-Guerrero O, Torre A, Vilatoba M, Castro Narro GE, Lumbreras Márquez MI, Navarro-Alvarez N. Risk factors for autoimmune liver disease recurrence after liver transplantation. World J Transplant 2025; 15(4): 106938
- URL: https://www.wjgnet.com/2220-3230/full/v15/i4/106938.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i4.106938